Cybin (NEO: CYBN) (OTCQB: CLXPF) has announced a key step forward in its focus on progressing psychedelic therapeutics. The company will be sponsoring a feasibility study of the Kernel Flow technology; the study is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/BW1Jn).
“We still have much to learn about what is occurring in the brain during a psychedelic experience,” said Cybin CEO Doug Drysdale. “This first-of-its-kind, Cybin-sponsored study using the Kernel Flow device aims to expand our physiological understanding of psychedelic pharmacotherapy. We are excited to be part of this pioneering journey with our partners at Kernel.”
Cybin announced a partnership with Kernel earlier this year. The two companies are working together to leverage Kernel’s proprietary Kernel Flow device for psychedelic-based studies and clinical trials. The Kernel Flow device is the first commercially scalable time-domain near-infrared spectroscopy (TD-fNIRS) system in history. The device uses quantitative neuroimaging technology that measures brain activity in real time when users wear the device during psychedelic treatments.
According to Cybin, Kernel Flow uses pulsed light to increase measured brain information. In contrast with electroencephalography (“EEG”) electrodes, which typically require gel on the head, or functional magnetic resonance imaging (“fMRI”) studies, which require a participant to lie in a scanner, the Flow device is a wearable helmet. The device has potential for broad use in neuroscientific or physiological studies of brain activity during psychedelic use; little direct neuroimaging research of psychedelic effects, in vivo, have been attempted until now, and that research has never been done with a wearable device.
The study will use the device to study ketamine, a dissociative injected anesthetic that blocks sensory perception and has been available by prescription in the United States since the 1970s for human and veterinary uses (https://ibn.fm/uv5Zk). A form of ketamine has been approved for treatment-resistant depression and is approved for use in depressed patients with acute suicidal ideation or behavior. In the United States, ketamine is a class III scheduled drug and is approved for use in hospitals and other medical settings as an anesthetic.
“Psychedelics have shown great promise for mental health and wellness, and Kernel’s collaboration with Cybin has the promise of offering increased scientific rigor for their development,” said Kernel founder and CEO Bryan Johnson.
Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades.…
BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies —…
Aggressive repurchase of its own stock by Earth Science Tech, a growing holding company focused…
Last year, Congress passed changes to Medicaid eligibility requirements and CMS was given a deadline to issue…
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. The…
Cardiovascular disease remains one of the most expensive health conditions in the United States. Cardio…